AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3044870 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (300 mg: 100 mg twice a day orally and 100 mg suppository at night)
Number of subjects: 40
Study 3044870 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium (75 mg: 25 mg twice daily orally and 25 mg suppository at night)
Number of subjects: 40
Study 3044870 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 40
Study 31786746 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbed repositioning pharyngoplasty (BRP)
Number of subjects: 0
Study 31786746 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study 29488900 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerine (0.4 mg)
Number of subjects: 42
Study 29488900 — intervention group
Group type: COMPARATOR
Intervention: Inorganic nitrate (beetroot juice, 12.9 mmol NO3)
Number of subjects: 42
Study 28415999 — intervention group
Group type: EXPERIMENTAL
Intervention: TALKING TIME intervention (telephone-based support groups)
Number of subjects: 88
Study 28415999 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 88
Study 25171664 — intervention group
Group type: EXPERIMENTAL
Intervention: W40 (40% of maximal isometric voluntary contraction)
Number of subjects: 20
Study 25171664 — intervention group
Group type: EXPERIMENTAL
Intervention: W70 (70% of maximal isometric voluntary contraction)
Number of subjects: 20
Study 25171664 — intervention group
Group type: COMPARATOR
Intervention: W40
Number of subjects: 20
Study 25171664 — intervention group
Group type: EXPERIMENTAL
Intervention: W70
Number of subjects: 20
Study 23910206 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mm miniscrews
Number of subjects: 105
Study 23910206 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mm miniscrews
Number of subjects: 105
Study 23910206 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mm miniscrews
Number of subjects: 105
Study 23910206 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniscrews placed with insertion torque greater than 10 Ncm
Number of subjects: 105
Study 23910206 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniscrews placed in less than approximately 3.8 mm of bone
Number of subjects: 105
Study 23910206 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniscrews placed within 1.4 mm of the root
Number of subjects: 105
Study 23910206 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniscrews in the maxilla
Number of subjects: 105
Study 23910206 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniscrews in the mandible
Number of subjects: 105
Study 21951683 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous peripheral blood stem cell transplantation (ASCT) after high-dose cyclophosphamide and busulfan
Number of subjects: 517
Study 21951683 — intervention group
Group type: COMPARATOR
Intervention: Intensive chemotherapy with etoposide and mitoxantrone
Number of subjects: 517
Study 21951683 — intervention group
Group type: COMPARATOR
Intervention: Overall survival
Number of subjects: 517
Study 19027413 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced energy density lunch meal
Number of subjects: 45
Study 19027413 — intervention group
Group type: COMPARATOR
Intervention: Regular lunch meal
Number of subjects: 45
Study 16634339 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised training
Number of subjects: 47
Study 16634339 — intervention group
Group type: COMPARATOR
Intervention: Home training
Number of subjects: 47
Study 12537035 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (no tryptophan)
Number of subjects: 33
Study 12537035 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nutritionally balanced drink containing tryptophan)
Number of subjects: 33
Study 12537035 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion
Number of subjects: 33
Study 12537035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 11082469 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TMS (20 subjects)
Number of subjects: 30
Study 11082469 — intervention group
Group type: COMPARATOR
Intervention: Sham (10 subjects)
Number of subjects: 30
Study 8705395 — intervention group
Group type: EXPERIMENTAL
Intervention: rBPI23 administered as a 5 or 30 min infusion at doses of 0.1 to 1 mg/kg
Number of subjects: 0
Study 8705395 — intervention group
Group type: EXPERIMENTAL
Intervention: rBPI23
Number of subjects: 0
Study 1510645 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg, twice daily)
Number of subjects: 7
Study 6611245 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle ergometry
Number of subjects: 46
Study 6611245 — intervention group
Group type: EXPERIMENTAL
Intervention: Short walks
Number of subjects: 46
Study 30415354 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 500 mg capsule orally before RYGB surgery
Number of subjects: 8
Study 30415354 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 500 mg capsule orally 2 months after RYGB surgery
Number of subjects: 8
Study 30415354 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 500 mg capsule orally before and after RYGB surgery
Number of subjects: 8
Study 30541506 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin plus metformin
Number of subjects: 1200
Study 30541506 — intervention group
Group type: COMPARATOR
Intervention: Insulin plus placebo
Number of subjects: 1200
Study 28119757 — intervention group
Group type: EXPERIMENTAL
Intervention: TAT-SOD applied to acupoints LI 20
Number of subjects: 0
Study 28119757 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle cream)
Number of subjects: 0
Study 28119757 — intervention group
Group type: COMPARATOR
Intervention: TAT-SOD applied directly to nasal cavity (TTN group)
Number of subjects: 0
Study 24454728 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal ART provision in arm A
Number of subjects: 0
Study 24454728 — intervention group
Group type: EXPERIMENTAL
Intervention: ART according to national guidelines in arm B
Number of subjects: 0
Study 24454728 — intervention group
Group type: COMPARATOR
Intervention: Control arm C
Number of subjects: 0
Study 22520141 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (PRV), RotaTeq(®), 3 doses at approximately 6, 10, and 14 weeks of age
Number of subjects: 5468
Study 20080470 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive use of lotion containing 3% urea, polidocanol, and hyaluronic acid
Number of subjects: 98
Study 20080470 — intervention group
Group type: COMPARATOR
Intervention: Standard use of lotion containing 3% urea, polidocanol, and hyaluronic acid
Number of subjects: 98
Study 18595261 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin‐converting enzyme inhibitors
Number of subjects: 370
Study 18595261 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blockers
Number of subjects: 370
Study 18595261 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta‐blockers
Number of subjects: 370
Study 18595261 — intervention group
Group type: EXPERIMENTAL
Intervention: Long‐acting calcium antagonists
Number of subjects: 370
Study 18595261 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin
Number of subjects: 370
Study 18595261 — intervention group
Group type: COMPARATOR
Intervention: Terazosin
Number of subjects: 370
Study 18595261 — intervention group
Group type: COMPARATOR
Intervention: Torasemide
Number of subjects: 370
Study 15751264 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hormone therapy (estrogen-progestin)
Number of subjects: 0
Study 15751264 — intervention group
Group type: COMPARATOR
Intervention: Other treatment arms of the WHI (not specified)
Number of subjects: 0
Study 11678968 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 3159
Study 11678968 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 3159
Study 11678968 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 3159
Study 11678968 — intervention group
Group type: EXPERIMENTAL
Intervention: Degree of physical activity in men
Number of subjects: 3159
Study 11678968 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and HbA1c adjusted values
Number of subjects: 3159
Study 11678968 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 3159
Study 11678968 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol, LDL-C, HDL-C and HDL-C subfractions
Number of subjects: 3159
Study 9702849 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 249
Study 9702849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 7526753 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophils from clinically normal cows
Number of subjects: 46
Study 7526753 — intervention group
Group type: COMPARATOR
Intervention: Neutrophils from cows with metritis
Number of subjects: 46
Study 7526753 — intervention group
Group type: COMPARATOR
Intervention: Neutrophils from cows with mastitis
Number of subjects: 46
Study 7526753 — intervention group
Group type: COMPARATOR
Intervention: Neutrophils from postparturient cows with abnormalities (retained placenta, metritis, mastitis)
Number of subjects: 46
Study 7526753 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophils preincubated alone in a 37 C water bath for 30 minutes
Number of subjects: 46
Study 2644581 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 24
Study 2644581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1087732 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L-5-hydroxytryptophan (L-5HTP)
Number of subjects: 0
Study 30664111 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined surfaces plyometric jump training (PJTc)
Number of subjects: 23
Study 30664111 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-surface plyometric jump training (PJTs)
Number of subjects: 23
Study 30664111 — intervention group
Group type: COMPARATOR
Intervention: Active control (CON)
Number of subjects: 23
Study 30346242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1183
Study 30346242 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 1183
Study 30346242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 1183
Study 27091535 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Internet‐based cognitive behavioral therapy for insomnia (ICBT‐i)
Number of subjects: 148
Study 27091535 — intervention group
Group type: COMPARATOR
Intervention: Active control treatment (ICBT‐ctrl)
Number of subjects: 148
Study 24998105 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with S‐(+)‐ketamine (25mg)
Number of subjects: 80
Study 24998105 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 80
Study 21494228 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Change
Number of subjects: 0
Study 21494228 — intervention group
Group type: COMPARATOR
Intervention: Health Education
Number of subjects: 0
Study 20515210 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (BMI)
Number of subjects: 1014
Study 20515210 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (BMI) + Parent-based intervention (PBI)
Number of subjects: 1014
Study 18175740 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain diet (hypocaloric, reduced by 500 kcal/d)
Number of subjects: 50
Study 18175740 — intervention group
Group type: COMPARATOR
Intervention: Refined-grain diet (hypocaloric, reduced by 500 kcal/d)
Number of subjects: 50
Study 15794787 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral desmopressin 400 microg
Number of subjects: 24
Study 15794787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 14649310 — intervention group
Group type: EXPERIMENTAL
Intervention: cilnidipine
Number of subjects: 0
Study 14649310 — intervention group
Group type: EXPERIMENTAL
Intervention: amlodipine
Number of subjects: 0
Study 14649310 — intervention group
Group type: COMPARATOR
Intervention: nifedipine CR
Number of subjects: 0
Study 10980763 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up visual fields with abnormalities (n = 748)
Number of subjects: 1637
Study 10980763 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up visual fields with unreliability (n = 258)
Number of subjects: 1637
Study 10980763 — intervention group
Group type: EXPERIMENTAL
Intervention: Retesting of originally abnormal and reliable visual fields (n = 703)
Number of subjects: 1637
Study 8784652 — intervention group
Group type: EXPERIMENTAL
Intervention: Zalospirone 45 mg/day
Number of subjects: 287
Study 8784652 — intervention group
Group type: EXPERIMENTAL
Intervention: Zalospirone 6 mg/day
Number of subjects: 287
Study 8784652 — intervention group
Group type: EXPERIMENTAL
Intervention: Zalospirone 15 mg/day
Number of subjects: 287
Study 8784652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study 1733381 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 2046
Study 1733381 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (adjusted for other risk factors)
Number of subjects: 2046
Study 6467858 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (50 mg/day) combined with 25-50 micrograms of 25 OH cholecalciferol (calcifediol) per day for 6-18 months (12 patients) and 31-58 months (9 patients)
Number of subjects: 19
Study 6467858 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6-18 months (9 patients)
Number of subjects: 19
Study 30777658 — intervention group
Group type: EXPERIMENTAL
Intervention: Testes with grade I varicocele
Number of subjects: 30
Study 30777658 — intervention group
Group type: EXPERIMENTAL
Intervention: Testes with grade II varicocele
Number of subjects: 30
Study 30777658 — intervention group
Group type: EXPERIMENTAL
Intervention: Testes with grade III varicocele
Number of subjects: 30
Study 30777658 — intervention group
Group type: COMPARATOR
Intervention: Contralateral testes with grade I varicocele
Number of subjects: 30
Study 30777658 — intervention group
Group type: COMPARATOR
Intervention: Contralateral testes with grade II varicocele
Number of subjects: 30
Study 30777658 — intervention group
Group type: COMPARATOR
Intervention: Contralateral testes with grade III varicocele
Number of subjects: 30
Study 30777658 — intervention group
Group type: EXPERIMENTAL
Intervention: Testes with varicocele (volume difference > 20%)
Number of subjects: 30
Study 30777658 — intervention group
Group type: COMPARATOR
Intervention: Contralateral testes (volume difference > 20%)
Number of subjects: 30
Study 30777658 — intervention group
Group type: EXPERIMENTAL
Intervention: Testes with varicocele (volume difference 0-20%)
Number of subjects: 30
Study 30777658 — intervention group
Group type: COMPARATOR
Intervention: Contralateral testes (volume difference 0-20%)
Number of subjects: 30
Study 29801402 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional health education program (THEP)
Number of subjects: 999
Study 29801402 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapping peer leaders using mobile phone prompts (PPHEP)
Number of subjects: 999
Study 29801402 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 999
Study 26497857 — intervention group
Group type: EXPERIMENTAL
Intervention: EHF1-3
Number of subjects: 79
Study 26497857 — intervention group
Group type: EXPERIMENTAL
Intervention: EHF8
Number of subjects: 79
Study 24112635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal 0.5 mg ranibizumab
Number of subjects: 36
Study 24112635 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care grid laser
Number of subjects: 36
Study 22834417 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (E2) gel 1.5 mg and oral micronized progesterone (P) 200 mg/day for the last 14 days of each cycle
Number of subjects: 100
Study 22834417 — intervention group
Group type: COMPARATOR
Intervention: Oral conjugated equine estrogens (CEE) 0.625 mg and oral medroxyprogesterone acetate (MPA) 5 mg for the last 14 days of each cycle
Number of subjects: 100
Study 20601257 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative nerve monitoring (IONM)
Number of subjects: 237
Study 20601257 — intervention group
Group type: COMPARATOR
Intervention: No IONM (visualization alone)
Number of subjects: 237
Study 17662759 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence self-efficacy (ASE)
Number of subjects: 980
Study 17662759 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational attainment (EA)
Number of subjects: 980
Study 16099600 — intervention group
Group type: EXPERIMENTAL
Intervention: Balsalazide (2250 mg, twice daily for 5 days before RT and 2 weeks after completion)
Number of subjects: 27
Study 16099600 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical-appearing, twice daily for 5 days before RT and 2 weeks after completion)
Number of subjects: 27
Study 16099600 — intervention group
Group type: EXPERIMENTAL
Intervention: Balsalazide
Number of subjects: 27
Study 16099600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 12237172 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy diet
Number of subjects: 54
Study 12237172 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1 g/day)
Number of subjects: 54
Study 12237172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 10545746 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplement (100 mg orally daily) in addition to RRT
Number of subjects: 50
Study 10545746 — intervention group
Group type: COMPARATOR
Intervention: RRT only
Number of subjects: 50
Study 7562887 — intervention group
Group type: EXPERIMENTAL
Intervention: Hawksley random zero sphygmomanometer (RZS)
Number of subjects: 24
Study 7562887 — intervention group
Group type: COMPARATOR
Intervention: Standard mercury sphygmomanometer (SMS)
Number of subjects: 24
Study 3615572 — intervention group
Group type: EXPERIMENTAL
Intervention: Zuclopenthixol (37 mg daily)
Number of subjects: 40
Study 3615572 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine (30 mg daily)
Number of subjects: 40
Study 3615572 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 40
Study 30150750 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg fluoxetine
Number of subjects: 42
Study 30150750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 27070980 — intervention group
Group type: EXPERIMENTAL
Intervention: Team development intervention implemented in 4 of 5 clinics
Number of subjects: 0
Study 27070980 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 25271034 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 degrees bed elevation
Number of subjects: 252
Study 25271034 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 degrees bed elevation
Number of subjects: 252
Study 25271034 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 degrees bed elevation
Number of subjects: 252
Study 25271034 — intervention group
Group type: COMPARATOR
Intervention: Supine position (control group)
Number of subjects: 252
Study 23734840 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g mesalazine suppository once daily for 4 weeks
Number of subjects: 0
Study 23734840 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppository once daily for 4 weeks
Number of subjects: 0
Study 23734840 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g mesalazine suppository
Number of subjects: 0
Study 20236174 — intervention group
Group type: EXPERIMENTAL
Intervention: FTLD-FUS
Number of subjects: 3
Study 20236174 — intervention group
Group type: COMPARATOR
Intervention: FTLD-TDP
Number of subjects: 3
Study 20236174 — intervention group
Group type: COMPARATOR
Intervention: FTLD-TAU
Number of subjects: 3
Study 18420315 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-valent pneumococcal conjugate vaccine with protein D of Haemophilus influenzae as a carrier (PncPD11)
Number of subjects: 0
Study 18420315 — intervention group
Group type: COMPARATOR
Intervention: 7-valent pneumococcal conjugate vaccine (PncCRM7)
Number of subjects: 0
Study 19560968 — intervention group
Group type: EXPERIMENTAL
Intervention: 15m square shuttle run test (SST)
Number of subjects: 45
Study 19560968 — intervention group
Group type: COMPARATOR
Intervention: 20 m multistage shuttle run test (MST)
Number of subjects: 45
Study 19560968 — intervention group
Group type: COMPARATOR
Intervention: Treadmill test (TT)
Number of subjects: 45
Study 19560968 — intervention group
Group type: EXPERIMENTAL
Intervention: SST
Number of subjects: 45
Study 15805366 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide (iNO)
Number of subjects: 108
Study 15805366 — intervention group
Group type: COMPARATOR
Intervention: Control (no iNO)
Number of subjects: 108
Study 12017793 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement
Number of subjects: 60
Study 12017793 — intervention group
Group type: COMPARATOR
Intervention: Dentin bonding agent alone
Number of subjects: 60
Study 12017793 — intervention group
Group type: COMPARATOR
Intervention: Dentin bonding agent in combination with flowable composite
Number of subjects: 60
Study 12017793 — intervention group
Group type: COMPARATOR
Intervention: Flowable compomer
Number of subjects: 60
Study 12017793 — intervention group
Group type: COMPARATOR
Intervention: Autopolymerizing composite
Number of subjects: 60
Study 9355815 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-family psycho-educational intervention
Number of subjects: 0
Study 9355815 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-EE key relatives
Number of subjects: 0
Study 9355815 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-family groups
Number of subjects: 0
Study 7678686 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline (130-390 mg/day)
Number of subjects: 12
Study 7678686 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (160-320 mg/day)
Number of subjects: 12
Study 7678686 — intervention group
Group type: COMPARATOR
Intervention: Control state
Number of subjects: 12
Study 3309186 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine and self-exposure
Number of subjects: 40
Study 3309186 — intervention group
Group type: COMPARATOR
Intervention: Placebo and self-exposure
Number of subjects: 40
Study 3309186 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 40